infusions of infliximab at a dose of 5 mg/kg at weeks 0, 2, 6, and every 8 weeks thereafter. In responders, treatment with CS is rapidly tapered over 8-10 weeks until withdrawal. As of October 2015, 26 BD patients with uveoretinitis and/or neuro-Behçet were in stable remission while receiving re-IFX infusions. However, a local health authority issued a rule stating that patients who did not reside in Prato should receive the current intravenous treatment in the hospitals of the area where they lived, and our institution would only conduct scheduled follow-up visits. Over the next few months, of 26 patients, 3 were switched to bio-IFX in their local hospitals and, as described below, all of them rapidly relapsed. Informed consent concerning all treatments was obtained from the three patients.
Case 1
A 32-year-old male presented in 2008 with a 6-year history of recurrent oral and genital ulcers, 1 episode of thrombophlebitis of the left leg, arthritis in the left knee and right ankle, and thrombosis of the central retinal vein of the right eye with visual loss. In the past, the patient had been diagnosed with BD in other hospitals, and had been treated with corticosteroids (CS), methotrexate (MTX) and Cyclosporin A (CsA) with frequent disease flare-ups requiring CS dose escalation. During the first visit in our center, the patient, who was still receiving CsA 5 mg/kg/day and prednisone 25 mg/day, presented severe uveitis and retinal vasculitis of the left eye with reduced best-corrected visual acuity (VA) (Snellen chart of 0.1-1.0 at a distance of 5 meters: 0.2), oral aphthosis, and left knee and left wrist arthritis. Treatment with re-IFX at a dose of 5 mg/kg was started and all clinical manifestations subsided after the third infusion. VA of the left eye improved to 0.7, and over the following 6 years treatment with re-IFX was continued, with sustained clinical remission. 
Case 2
A 40-year old woman with BD complicated by bilateral posterior uveitis and cerebral vasculitis had been treated in our center with IFX at 5 mg/kg iv since 2010. The patient achieved a stable disease remission and IFX infusions were continued until November 2015. The patient was a resident of another city of Tuscany, where she was switched to bio-IFX (Inflectra) at a dose of 5 mg/kg. After the third infusion, she experienced a loss of response with relapse of bilateral posterior uveitis, fever, pulsating headache, dysarthria, loss of balance, right-sided hemiparesis and cognitive impairment. An MRI of the brain enhanced with gadolinium showed the presence of a large involving the pons and extending to the midbrain. Treatment with intravenous methylprednisolone (1 g daily for 5 days) concomitantly administered with adalimumab 40 mg/eow/sc was started. All clinical manifestations remitted within 1 month and the patient is still in clinical remission.
Case 3
A 26-year old male with BD complicated by neurological and intestinal involvement has been followed at our center since 2009. The patient was resistant to MTX, and cyclophosphamide, and a high dose of CS was required to control clinical manifestations. In early 2010, IFX 5 mg/kg was administered to the patient, and a rapid response and complete disease remission was observed. Treatment with CS was withdrawn over a 4-month period and IFX treatment was continued with maintenance of remission during the following 5 years. As he was a resident of the Piemonte region, from November 2015 he was switched to bio-IFX (Remsima), with infusions of 5 mg/kg administered every 8 weeks. After the second infusion, oral aphthosis, papulopustulosis, and neurological and intestinal manifestations recurred. In February 2016, at the follow-up visit in our center, the flare-up was confirmed and after treatment with intravenous methylprednisolone (1 g daily for 5 days) and adalimumab (40 mg/eow/sc), a rapid improvement of the signs and symptoms of BD was observed, with complete remission after 2 months.
Discussion
The exchangeability and automatic substitution of re-IFX with bio-IFX is debated, and in Europe the decision is entrusted to a single country (8) .
There are a few studies on switching from re-IFX to bio-IFX in rheumatoid arthritis, spondyloarthritis, and inflammatory bowel diseases. Most of these studies seem to be reassuring in terms of efficacy maintenance and safety (9) (10) (11) . However, in a recent report, of 23 patients with stable disease remission who were switched from re-IFX to bio-IFX, 7 experienced disease flare-ups after a mean interval of 2 months (12) . Therefore, the authors raised concerns regarding the exchangeability of treatments in the absence of consolidated data from real cases. The same concerns have also been expressed by the Canadian Agency for Drugs and Technologies in Health, which has recently stated that the current evidence does not show a sustained effectiveness and longterm safety of bio-IFX, and that there is not enough data on the occurrence and impact of anti-drug antibodies (ADAs) over time (13) .
Our experience with the 3 BD patients who were successfully treated with re-IFX and who experienced recurrence of uveitis and of neuro-Behçet soon after switching to bio-IFX appears to reinforce skepticism regarding the exchangeability and automatic substitution of reference re-IFX with the biosimilar drug. In the absence of a valid explanation, we could only hypothesize that the rapid failure of bio-IFX in our 3 patients might be related to the development of ADAs against re-IFX. In our clinical practice, we do not examine circulating ADAs and drug serum levels in patients receiving re-IFX, but the hypothesis of ADA-induced loss of efficacy for bio-IFX seems to be confirmed by a recent paper showing cross-reactivity of anti-re-IFX antibodies and bio-IFX (14) . The higher proportion of antibody molecules with truncated C-terminal lysines, the differences in site-specific deamination, the lower level of afucosylated glycans, and other minor molecular and pharmacological differences of bio-IFX found in the EMA comparability exercise [6] may enhance the neutralizing action of antire-IFX antibodies in patients switched to the biosimilar drug.
Technical problems including defective transport, storage and drug solution preparation could be an alternative explanation for the loss of efficacy of bio-IFX. This possibility was duly investigated, and it was found that all procedures had been properly conducted.
In conclusion, the rapid disease relapse observed in our 3 patients with BD soon after switching from re-IFX to bio-IFX further reinforces the claims that suggest caution concerning the automatic substitution of one treatment with the other. The loss of efficacy of bio-IFX may be related to the development of ADAs, and in order to verify this hypothesis, further investigations need to be conducted.
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